临床试验表明,大剂量药物涂层球囊(HD-DCB)和基于聚合物的药物洗脱支架(PB-DES)治疗股pop动脉(FP)疾病具有良好的效果。然而,哪个会更好,保持不变。
■本研究使用了2个大型多中心前瞻性药物涂层球囊(DCB)和药物洗脱支架(DES)注册表的数据库。该研究包括2470例接受IN治疗的症状性FP病变患者。在69个中心接触海军上将DCB或EluviaDES。进行了基于倾向评分的配对分析。主要终点为1年再狭窄率。次要终点是1年再闭塞率,靶病变血运重建(TLR),急性血栓形成,旁路转换,严重截肢,主要不良肢体事件(男性),和全因死亡。
■共有1535名患者接受了HD-DCB治疗,935例患者接受PB-DES治疗。倾向得分匹配提取了678对,基线特征无显著组间差异。PB-DES组1年再狭窄率明显低于HD-DCB组(16.0%vs22.0%,p=0.016)。其他端点(再闭塞率,TLR,急性血栓形成,旁路转换,严重截肢,Male,和全因死亡)在组间没有差异。没有基线特征对HD-DCB和PB-DES与再狭窄风险的相关性有任何显著的交互作用(均p>0.05)。
■这项研究表明,1年TLR,再闭塞率,尽管PB-DES组的再狭窄较低,但PB-DES组和HD-DCB组之间的其他终点没有差异。
结论:基于聚合物的DES组的一年再狭窄率明显低于大剂量DCB组。然而,两组之间的其他终点没有差异.
UNASSIGNED: Clinical trials have demonstrated that high-dose drug-coated balloon (HD-DCB) and polymer-based drug-eluting stent (PB-DES) treatments for femoropopliteal (FP) artery disease have favorable outcomes. However, which one would be better remained unrevealed.
UNASSIGNED: This study used the databases of 2 large-scale multicenter prospective drug-coated balloon (DCB) and drug-eluting stent (DES) registries. The study included 2470 patients with symptomatic FP lesion treated with IN.PACT Admiral DCB or Eluvia DES at 69 centers. A propensity-score-based paired analysis was conducted. Primary endpoint was 1-year
restenosis rate. Secondary endpoints were 1-year reocclusion rate, target lesion revascularization (TLR), acute thrombosis, bypass conversion, major amputation, major adverse limb event (MALE), and all-cause death.
UNASSIGNED: A total of 1535 patients were treated with HD-DCB, and 935 patients were treated with PB-DES. The propensity-score matching extracted 678 pairs, with no remarkable intergroup difference in baseline characteristics. The 1-year
restenosis rate was significantly lower in the PB-DES group than in the HD-DCB group (16.0% vs 22.0%, p=0.016). The other endpoints (reocclusion rate, TLR, acute thrombosis, bypass conversion, major amputation, MALE, and all-cause death) did not differ between the groups. No baseline characteristics had any significant interaction effect on the association of HD-DCB vs PB-DES with
restenosis risk (all p>0.05).
UNASSIGNED: This study demonstrated that the 1-year TLR, reocclusion rate, and other endpoints did not differ between the PB-DES group and the HD-DCB group despite the lower
restenosis in the PB-DES group.
CONCLUSIONS: One-year
restenosis rate was significantly lower in the polymer-based DES group than in the high-dose DCB group for foemoropopliteal disease. However, there is no difference in the other endpoints between two groups.